Evidence map›Paper›PMID 31965535›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Regorafenib and ginsenoside combination therapy: inhibition of HepG2 cell growth through modulating survivin and caspase-3 gene expression.

B Wang, F Wang, A Ding, H Zhao, X Bu

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 27 citations in OpenAlex.

  1. Synergistic mechanisms and clinical translation of regorafenib combination therapies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Research Progress on the Anticancer Effect of Ginsenoside Rh1.Current issues in molecular biology · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Anticancer Activities of Ginsenosides, the Main Active Components of Ginseng.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

B WangWard 3, Department of Hepatology, Jinan Infectious Disease Hospital Affiliated to Shandong University, Jinan, 250021, People's Republic of China.
F WangDepartment of Respiration, Jinan Infectious Disease Hospital Affiliated to Shandong University, Jinan, 250021, People's Republic of China.
A DingWard 4, Department of Hepatology, Jinan Infectious Disease Hospital Affiliated to Shandong University, Jinan, 250021, People's Republic of China.
H ZhaoWard 2, Department of Liver Cirrhosis, Jinan Infectious Disease Hospital Affiliated to Shandong University, Jinan, 250021, People's Republic of China.
X BuWard 1, Department of Liver Cirrhosis, Jinan Infectious Disease Hospital Affiliated to Shandong University, No. 22029 Jingshi Road, Jinan, 250021, People's Republic of China. bh8dvq@163.com.ORCID http://orcid.org/0000-0001-8750-1171
Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis work aimed to investigate the inhibitory effect of regorafenib in combination with ginsenoside on the growth of HepG2 liver cancer cells.

methodsHepG2 liver cancer cells were divided into blank control group, regorafenib single-drug group, ginsenoside single-drug group, and regorafenib/ginsenoside combination group. Cells in the regorafenib single-drug group were treated with regorafenib at 0.25 mg/L, 0.5 mg/L, and 1 mg/L, respectively, while cells in the ginsenoside single-drug group were treated with ginsenoside at 5.0 mg/L, 10.0 mg/L, and 20.0 mg/L, respectively. HepG2 cell proliferation, expression of survivin mRNA, and the apoptotic effector caspase-3 in HepG2 liver cancer cells were assessed.

resultsAn inhibitory effect on the growth of HepG2 liver cancer cells was observed for both the single-drug therapies and the combination therapy. The synergistic inhibitory effect presented by the combination therapy was dependent on the gradient concentration and treatment time. RT-qPCR results showed that both regorafenib and ginsenoside significantly reduced the expression of survivin mRNA in HepG2 liver cancer cells and the expression level of survivin mRNA in the regorafenib/ginsenoside combination group was much lower than those in the regorafenib single-drug group and ginsenoside single-drug group. The two drugs demonstrated synergistic inhibitory effect when used in combination.

conclusionsThe findings in this study offered a theoretical insight into clinical use of regorafenib and ginsenoside for treatment of liver cancer.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisCaspase 3Cell ProliferationDrug SynergismGinsenosidesHep G2 CellsHumansLiver NeoplasmsPhenylurea CompoundsProtein Kinase InhibitorsPyridinesSurvivinBIRC5 protein, humanCASP3 protein, humanCaspase 3GinsenosidesPhenylurea CompoundsProtein Kinase InhibitorsPyridinesregorafenibSurvivinApoptosisGinsenosideHepG2 cellsLiver cancer cellsRegorafenib

Identifiers

PMID31965535
OpenAlexW3002197729

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.